ACIU - ACイミュ―ン (AC Immune SA) ACイミュ―ン

 ACIUのチャート


 ACIUの企業情報

symbol ACIU
会社名 AC Immune SA (ACイミュ―ン)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases such as Down syndrome glaucoma and Parkinson''s and focuses on producing therapeutic and diagnostic product candidates using SupraAntigen and Morphomer technology platforms. The Company''s pipeline includes Crenezumab ACI-24 Anti-Tau antibody Morphomer Tau Tau-PET imaging agent Morphomer Abeta and Morphomer alpha-syn among others.   ACイミュ―ンはスイスのバイオ医薬品企業。臨床段階で、細胞内のタンパク質の折りたたみ異常に起因する神経変性疾患の特定や治療薬の開発に従事する。広範囲の神経変性疾患を対象にパ―キンソン病、ダウン症、緑内障の予防や診断、治療に対応するために抗体や小分子、ワクチンを作成する。本社はラウサネ。   AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in Precision Medicine for neurodegenerative diseases. The Company is utilizing two proprietary discovery platforms, SupraAntigenTM and MorphomerTM, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with five currently in clinical trials. It has collaborations with major pharmaceutical companies including Roche/Genentech, Lilly and Janssen.
本社所在地 EPFL Innovation Park Building B Lausanne 1015 CHE
代表者氏名 Martin Velasco マーティンベラスコ
代表者役職名 Chairman of the Board of Directors
電話番号 +41 21-345-9121
設立年月日 37653
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数
url www.acimmune.com
nasdaq_url https://www.nasdaq.com/symbol/aciu
adr_tso
EBITDA EBITDA(百万ドル) -28.79702
終値(lastsale) 7.35
時価総額(marketcap) 495115771.5
時価総額 時価総額(百万ドル) 527.14420
売上高 売上高(百万ドル) 21.15660
企業価値(EV) 企業価値(EV)(百万ドル) 424.17964
当期純利益 当期純利益(百万ドル) -27.61319
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 AC Immune SA revenues increased 26% to SF3.5M. Net loss increased 4% to SF22.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Operating Expense - R&D increase of 57% to SF15.2M (expense) Labor_Related Expenses in R&D increase from SF2.2M to SF5.4M (expense).

 ACIUのテクニカル分析


 ACIUのニュース

   AC Immune gets $0.5M grant to develop diagnostic imaging agent for Parkinson''s  2022/09/01 12:30:16 Seeking Alpha
AC Immune (ACIU) said it received a new grant of $0.5M from the Michael J
   AC Immune KOL Webinar on the Potential Benefits of Vaccines for Alzheimer''s and Parkinson''s Diseases  2022/08/24 20:05:00 Benzinga
Vaccines can provide safe, long-lasting immunity, and logistical advantages compared to other treatment modalities Integrating its precision medicine approach, AC Immune is advancing three clinical-stage vaccines targeting Tau, Abeta and α-synuclein Precisely targeted active immunotherapy may enable prevention of pathological pathways before the occurrence of irreversible neuronal damage LAUSANNE, Switzerland, Aug. 24, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU ), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today hosted key opinion leader (KOL) Cynthia A. Lemere, Ph.D., of the Ann Romney Center for Neurologic Diseases at Brigham & Women''s Hospital and Harvard Medical School, Boston, for a webinar focused on vaccines to treat and prevent Alzheimer''s and Parkinson''s diseases. Over 180 participants from the investment and biopharmaceutical industries registered to attend the webinar, which included presentations from Dr.
   AC Immune to Host Key Opinion Leader Webinar on Vaccinations to Treat and Prevent Alzheimer''s and Parkinson''s Diseases  2022/08/11 11:30:00 Benzinga
Webinar to take place on Wednesday, August 24 th at 10:00 AM ET / 4:00 PM CET Discussion to focus on novel therapeutic approaches and the selection of biomarkers and target proteins for active vaccination approaches LAUSANNE, Switzerland, Aug. 11, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU ), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will host a key opinion leader (KOL) webinar on vaccinations to treat and prevent Alzheimer''s and Parkinson''s diseases on Wednesday, August 24, 2022 at 10:00 AM ET / 4:00 PM CET. The webinar will feature a presentation from KOL Cynthia A. Lemere, Ph.D., of the Ann Romney Center for Neurologic Diseases at Brigham & Women''s Hospital and Harvard Medical School in Boston. During her presentation, Dr. Lemere will discuss the current immunotherapy landscape and novel therapeutic approaches to treat and prevent neurodegenerative diseases, with a focus on biomarkers and target proteins for active vaccination approaches.
   AC Immune to Host Key Opinion Leader Webinar on Vaccinations to Treat and Prevent Alzheimer’s and Parkinson’s Diseases  2022/08/11 11:30:00 Wallstreet:Online
Webinar to take place on Wednesday, August 24th at 10:00 AM ET / 4:00 PM CET Discussion to focus on novel therapeutic approaches and the selection of biomarkers and target proteins for active vaccination approaches LAUSANNE, Switzerland, Aug. 11, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (Nasdaq: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative
   AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update  2022/07/28 11:30:00 GlobeNewswire
LAUSANNE, Switzerland, July 28, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported results for the quarter ended June 30, 2022, and provided a corporate update.
   Mid-Afternoon Market Update: Dow Dips 900 Points; AC Immune Shares Slide  2022/06/16 19:00:12 Benzinga
U.S. stocks traded lower toward the end of trading, after the Federal Reserve raised fed funds rates by 0.75% to a new target range of between 1.5% and 1.75% on Wednesday. The Dow traded down 2.97% to 29,756.66 while the NASDAQ fell 4.73% to 10,573.75. The S&P also fell, dropping, 3.87% to 3,643.32. Also check this: 3 Stocks Under $1 Insiders Are Buying Leading and Lagging Sectors Consumer staples shares fell by just 0.9% on Thursday. Meanwhile, top gainers in the sector included RLX Technology Inc. (NYSE: RLX ), up 7% and MedAvail Holdings, Inc. (NASDAQ: MDVL ) up 7%. In trading on Thursday, energy shares tumbled by 6.2%. Top Headline US initial jobless claims fell by 3,000 to 229,000 in the week ended June 11th, compared to market estimates of 210,000. Equities Trading UP Sidus Space, Inc. (NASDAQ: SIDU ) shares shot up 75% to $8.19. Sidus Space shares jumped 225% on Wednesday after the company announced it is part of Collins Aerospace team which was awarded NASA''s Exploration Extravehicular Activity services contract with a potential value of $3.5 billion.
   ACIU stock leads selloff in Alzheimer’s space after trial setback (NASDAQ:ACIU)  2022/06/16 15:44:12 Seeking Alpha
A group of low cap biotechs are leading a selloff among Alzheimer’s drug developers after Roche (RHHBY) (RHHBF) announced on Thursday that their experimental drug for the memory…
   Bone Biologics, Akero top healthcare gainers; AC Immune, Arcellx lead losers'' pack  2022/06/16 14:08:56 Seeking Alpha
Bone Biologics (BBLG) +13%. Akero Therapeutics AKRO +10%. AC Immune ACIU -17%. Arcellx ACLX -17%.
   Futures Crash, Dow Down 600 As Recession Reality Sets In  2022/06/16 12:25:43 Zero Hedge
Futures Crash, Dow Down 600 As Recession Reality Sets In In our preview of how to trade the Fed''s 75bps rate hike , we said to expect a " kneejerk move higher (especially if we get an outsized hike, hinting the Fed is hoping to catch up to the curve), then a gradual drift lower " (a reco which was later echoed by Goldman ). Sure enough, in the aftermath of the FOMC announcement yesterday, we got the knejerk move higher… and then overnight, the drift lower has also appeared tight on schedule, with futures tumbling in the US, undoing the entire post-FOMC move higher, and dragging global stocks lower as traders come to grips with the realization that 75bps of hikes - far from bullish - means that a recession is now on deck. As a result, S&P futures were down 2.2%, tumbling as much as 130 points from overnight session highs, while Dow futures puked a whopping 600 points as central banks lose control over markets. European stocks headed for a 16-month low and Chinese Internet shares dropped in premarket New York trading And speaking of losing control, while normally yields would be tumbling ahead of a recession, this time they are doing the opposite with 10Y yields blowing out just shy of 3.50%, up 20 bps on the session after sliding following the biggest Fed hike in 28 years, as the bond market is starting to price in the uglier stagflation part of the coming recession, while stocks focus on the collapse in spending. “The volatility in bond markets is definitely not over,” Jasmin Argyrou, director and portfolio manager at Credit Suisse Private Bank, said on Bloomberg Television. “The likelihood is that policy rates in the US may need to go to a more restrictive stance than even the market is pricing in.” After the Fed raised interest rates by the most since 1994, Powell indicated a monetary stance similar to that of Paul Volcker, who broke the back of elevated inflation four decades ago but paid a price in the form of soaring unemployment and a credit squeeze.
   AC Immune shares slide 15% premarket after trial of Alzheimer''s treatment misses its main goals  2022/06/16 10:39:52 MarketWatch
Shares of biotech AC Immune SA slid 15% in premarket trade Thursday, after the company said a a trial of a treatment for Alzheimer''s disease failed to slow or prevent cognitive decline in patients with a specific genetic mutation that causes early-onset disease. The trial involved 252 people who are members of the world''s biggest extended family with Autosomal Dominant Alzheimer''s Disease, or ADAD, in Colombia. Some two thirds of those enrolled had the Presenilin 1 E280A mutation which typically causes cognitive impairment due to Alzheimer''s disease around age 44. The participants were randomized to receive the treatment called crenezumab or placebo over a period of five to eight years. Crenezumab was well tolerated and no new safety issues were identified. The company will present initial data at the Alzheimer''s Association International Conference on August 2. "While we are disappointed that the primary endpoints were not met, crenezumab''s safety profile and the favorable numerical differences observed across primary, secondary and exploratory endpoints, warrant further analyses of the data," AC Immune CEO Dr.
   AC Immune CFO Joerg Hornstein to depart  2022/04/08 11:40:42 Seeking Alpha
AC Immune (ACIU) has announced that CFO Joerg Hornstein will leave the company in the second half to pursue a new opportunity. Christopher Roberts, Associate Vice President, Finance,…
   Lundbeck Names Joerg Hornstein New CFO  2022/04/08 11:37:18 Wallstreet:Online
(PLX AI) – Lundbeck says Joerg Hornstein to join company as Chief Financial Officer and Head of Corporate Functions.He will assume the role no later than September 1, 2022Comes from AC Immune, a clinical-stage biopharmaceutical company specialized …
   AC Immune KOL Webinar on First Clinical Proof of Concept for Alpha-synuclein Diagnostic Shows Breakthrough Potential for Neurodegenerative diseases  2022/03/30 11:58:53 Benzinga
a-syn PET tracer, ACI-12589, clinically validated in MSA, potentially enables accelerated development of targeted therapeutics and additional a-syn diagnostics Another first for validated Morphomer ® discovery technology platform in developing small molecules able to selectively target pathological human proteins AC Immune pipeline includes a-syn diagnostic and multiple a-syn therapeutic candidates AC Immune on track to deliver seven clinical data readouts in 2022 LAUSANNE, Switzerland, March 30, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU ), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, hosted leading research scientist and key opinion leader Dr. Oskar Hansson for a webinar focused on a-synuclein as a diagnostic and therapeutic target in neurodegenerative diseases. AC Immune and Dr Hansson reported at the recent AD/PD™ conference , data showing that AC Immune''s wholly owned a-syn PET tracer ACI-12589 was the first-ever radiotracer to distinguish multiple system atrophy (MSA) from other a-synucleinopathies, i.e.
   AC Immune Non-GAAP EPS of -CHF0.99  2022/03/22 11:50:13 Seeking Alpha
AC Immune press release (ACIU): FY Non-GAAP EPS of -CHF0.99.As of December 31, 2021 the Company had a total cash balance of CHF 198.2 million, composed of CHF 82.2 million…
   AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update  2022/03/22 11:30:00 GlobeNewswire
Seven clinical data readouts expected in 2022 Three vaccines, targeting Tau, Abeta and alpha-synuclein, advancing in 2022 Semorinemab Phase 2 Lauriet trial: additional fluid biomarker data expected in H2 2022 Initiation of ACI-24 anti-Abeta vaccine Phase 1b/2 trial in patients with Alzheimer’s disease (AD) and people living with Down syndrome (DS) expected in H1 2022 AD/PD™ Conference: ACI-12589 identified as a reliable and accurate PET tracer for alpha-synucleinopathies (e.g. MSA) Strong financial position of CHF 198.2 million ensures the Company is fully financed through at least Q1 2024

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ACイミュ―ン ACIU AC Immune SA)

 twitter  (公式ツイッターやCEOツイッターなど)